Axsome Therapeutics (AXSM) IND for AXS-05 Phase 2/3 Trial in AD Cleared by FDA
Tweet Send to a Friend
Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced that its Investigational New Drug Application (IND) for AXS-05 in the treatment of agitation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
